Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ C4402881!4402881 !25932234     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25932234 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25932234 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Int+J+Clin+Exp+Med 2015 ; 8 (2 ): 2778-83 Nephropedia Template TP {{tp|p=25932234 |t=2015. Prothrombin complex concentrates utility for warfarin-associated hemorrhage |pdf=|usr=}}{{25932234 }} gab.com Text Prothrombin complex concentrates utility for warfarin-associated hemorrhage JO: Int J Clin Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=25932234 #FOAvip INTRODUCTION: Prothrombin Complex Concentrate (PCC) for reversal of warfarin is the main therapeutic option in cases of life-threatening bleeding. Aim of the study was to investigate for using 4-factor PCC brought to the therapeutic levels of International Normalized Ratio (INR) values in cases of life-threatening bleeding in Emergency Department. METHODS: This retrospective cohort study was performed in a tertiary care university emergency department. Patients with active bleeding who were taking warfarin with INR levels of ?1.5, and had received 4-factor prothrombin complex concentrate for treatment were included in to study. RESULTS: A total of 75 patients were included in the study. The median age of the study participants was 68 (minimum 23 to maximum 87) years and 45.3% (n = 34) of them were male. INR levels was normalized all patients who were received 4-factor PCC. Red blood cell (RBC) was transfused in 16 patients (21%) because of the low hemoglobin levels. Mean unite of the RBC packet was 2,75. The lengths of hospital stay of receiving 4-factor PCC rate were determined 4.9 ± 8.7 days. No thrombotic complications or adverse drug reactions were observed after 4-factor PCC administration in any of the patients. CONCLUSIONS: In our study 4-factor PCC was found to be effective and safe in rapidly reversing the effects of warfarin. Twit Text FOAVip Prothrombin complex concentrates utility for warfarin-associated hemorrhage ????Int J Clin Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=25932234 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25932234 #FOAvip English Wikipedia <ref>{{Cite pmid|25932234 }}</ref> Prothrombin complex concentrates utility for warfarin-associated hemorrhage #MMPMID25932234 Soyuncu S ; Aslan S ; Mutlu H ; Bektas F Int J Clin Exp Med 2015[]; 8 (2 ): 2778-83 PMID25932234 show ga INTRODUCTION: Prothrombin Complex Concentrate (PCC) for reversal of warfarin is the main therapeutic option in cases of life-threatening bleeding. Aim of the study was to investigate for using 4-factor PCC brought to the therapeutic levels of International Normalized Ratio (INR) values in cases of life-threatening bleeding in Emergency Department. METHODS: This retrospective cohort study was performed in a tertiary care university emergency department. Patients with active bleeding who were taking warfarin with INR levels of ?1.5, and had received 4-factor prothrombin complex concentrate for treatment were included in to study. RESULTS: A total of 75 patients were included in the study. The median age of the study participants was 68 (minimum 23 to maximum 87) years and 45.3% (n = 34) of them were male. INR levels was normalized all patients who were received 4-factor PCC. Red blood cell (RBC) was transfused in 16 patients (21%) because of the low hemoglobin levels. Mean unite of the RBC packet was 2,75. The lengths of hospital stay of receiving 4-factor PCC rate were determined 4.9 ± 8.7 days. No thrombotic complications or adverse drug reactions were observed after 4-factor PCC administration in any of the patients. CONCLUSIONS: In our study 4-factor PCC was found to be effective and safe in rapidly reversing the effects of warfarin. äProthrombin complex concentrates utility for warfarin-associated hemor(epmc).pdf DeepDyve Pubget Overpricing